Literature DB >> 22815080

APOE genotype in the diagnosis of Alzheimer's disease in patients with cognitive impairment.

Xiaoyan Sun1, Joyce Nicholas, Aljoeson Walker, Mark T Wagner, David Bachman.   

Abstract

BACKGROUND: Although an association between the apolipoprotein E (APOE) ε4 allele and increased risk of Alzheimer's disease (AD) is established, the utility of APOE genotyping in the clinical diagnosis of AD is still under investigation.
METHODS: Medical records of 89 patients with cognitive impairment and APOE genotype data underwent a retrospective review.
RESULTS: Comparison of age, age at onset, education, Mini-Mental State Examination, months of follow-up, and family history of dementia did not reveal statistical difference among the patients with different APOE genotypes. The APOE ε4 carriers had a higher percentage of AD diagnoses after a median 16 months follow-up than non-APOE ε4 carriers. The APOE ε4 designation had a high sensitivity and high positive predictive value for the diagnosis of AD but a low negative predictive value and specificity.
CONCLUSIONS: The APOE genotyping may be helpful in diagnosing AD especially in patients presenting with atypical features or early age of onset of dementia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22815080     DOI: 10.1177/1533317512452037

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  5 in total

1.  Apolipoprotein E genotyping and questionnaire-based assessment of lifestyle risk factors in dyslipidemic patients with a family history of Alzheimer's disease: test development for clinical application.

Authors:  H K Lückhoff; M Kidd; S J van Rensburg; D P van Velden; M J Kotze
Journal:  Metab Brain Dis       Date:  2016-02       Impact factor: 3.584

2.  Aberrant apolipoprotein E expression and cognitive dysfunction in patients with poststroke depression.

Authors:  Zhaohui Zhang; Junlin Mu; Jing Li; Wenqiang Li; Jinggui Song
Journal:  Genet Test Mol Biomarkers       Date:  2012-11-21

3.  Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers.

Authors:  Sergio Veiga; Andrés Rodríguez-Martín; Guillermo Garcia-Ribas; Ignacio Arribas; Miriam Menacho-Román; Miguel Calero
Journal:  Sci Rep       Date:  2020-02-07       Impact factor: 4.379

4.  Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort.

Authors:  Carlos Aguilar; J-Sebastian Muehlboeck; Patrizia Mecocci; Bruno Vellas; Magda Tsolaki; Iwona Kloszewska; Hilkka Soininen; Simon Lovestone; Lars-Olof Wahlund; Andrew Simmons; Eric Westman
Journal:  Front Aging Neurosci       Date:  2014-07-14       Impact factor: 5.750

5.  Web-Based Intervention Effects on Mild Cognitive Impairment Based on Apolipoprotein E Genotype: Quasi-Experimental Study.

Authors:  Anthoula C Tsolaki; Magda Tsolaki; Niki Pandria; Eftychia Lazarou; Olymbia Gkatzima; Vasiliki Zilidou; Maria Karagianni; Zafiroula Iakovidou-Kritsi; Vasilios K Kimiskidis; Panagiotis D Bamidis
Journal:  J Med Internet Res       Date:  2020-05-07       Impact factor: 5.428

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.